Boxing can take the fight to Parkinson’s Disease

Press release:

When we think of boxing, it’s understandable many of us wouldn’t associate it with being ‘good’ for our brains.

However, new Edith Cowan University (ECU) research undertaken in partnership with The Perron Institute and boxer Rai Fazio has shown the sport — without an opponent — could be a valuable way for people suffering Parkinson’s Disease (PD) to improve their quality of life.

Also collaborating with Sir Charles Gairdner Hospital and the University of Western Australia, ECU researchers had 10 people with early-stage PD perform three one-hour boxing sessions per week, over 15 weeks.

Continue reading “Boxing can take the fight to Parkinson’s Disease”

Study shows significant benefit of PolarCap® in recovery from sports-related concussions

Press release:

PolarCool AB (publ), a Swedish medical device company focusing on treatment of sports-related traumatic brain injury (TBI) and whiplash, today announced that it has submitted a 510(k) pre-market notification to the U.S. Food and Drug Administration (FDA) for the PolarCap® System.

This submission follows publication of statistically significant clinical results in the scientific journal Concussion, showing clear benefit for use of the PolarCap® System in the treatment of concussions among players of 15 elite Swedish Ice-Hockey teams in the Swedish Hockey Leagues (SHL).

The incidence of sports-related concussions is a significant national health concern in Sweden, as it is here in the U.S., and there is growing evidence that repetitive traumatic brain injury can cause long-term changes in brain structure and function. This is of particular concern in the field of contact sports, such as ice hockey, where available treatment options are limited.

“With this important FDA submission, we are paving the way for the first-ever sports-related TBI treatment model,” said Martin Waleij, PolarCool Chairman of the Board. “Supported by robust clinical evidence enabling players to safely return to play much earlier, our 510(k) submission is the first step in the FDA review process. We look forward to this review and are confident that speedy clearance for the PolarCap® System is on the horizon.”

The study, led by investigators from Lund University at Skåne University Hospital in Lund, Sweden, Luleå University of Technology in Luleå, and BrainCool AB, represents the largest study population focused on sports-related concussion treatment in Sweden or the U.S., and shows statistical benefits of therapeutic cooling using the PolarCap® System head and neck cooling technology.

“Publication of these study results in the journal Concussion marks a significant milestone for sports medicine around the globe,” said Erik Andersson, Chief Executive Officer of PolarCool, maker of the PolarCap® System that was used in the Lund study. “We are eager to proceed with larger studies and to partner with academic medical centers and professional sports organizations to further validate the benefits of this medical cooling technology–with the ultimate goal of improving both short- and long-term safety for players of all contact sports.”

The Swedish Hockey League, the players organization SICO and PolarCool are actively collaborating to improve player safety. Two PolarCap® Systems are available at all games and the league is working to establish a standardized acute treatment method concussion injuries.

“It is very positive that we can constitute that the introduction of the Polar Cap has meant fewer long time absences among players that were treated by cooling directly after a concussion, with this treatment we have another tool to use (against head injuries),” said SHL Sports Director & Vice CEO Johan Hemlin in a recent SHL press release.

Fifteen teams from elite ice-hockey leagues for males in Sweden were given the option to participate in the intervention group (receiving selective head-neck cooling after a sports-related concussion) or the control group (standard sports-related concussion management). Selective head-neck cooling was initiated at a mean of 12.3 ± 9.2 min after the concussion in 29 players, and 52 SRC controls received standard management. Results showed significant benefits of cooling in treating concussions with a median time to return to play for the players who underwent cooling of 7 days, versus 12 days for those who did not. The study also shows promising reduction in the proportion of long-term absence, which can be as long as three weeks or more, among treated players.

Exercise can help support recovery of patients with lasting COVID symptoms, study finds

Press release:

Patients with lasting symptoms of COVID-19 who completed a six week, supervised rehabilitation programme demonstrated significant improvements in exercise capacity, respiratory symptoms, fatigue and cognition, according to researchers at the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre – a partnership between Leicester’s Hospitals, the University of Leicester and Loughborough University.

The study, which is published in the journal Chronic Respiratory Disease today (Friday 7 May 2021), followed thirty patients who took part in face-to-face exercise rehabilitation classes twice a week over a period of six weeks. The programme included aerobic exercise, such as walking or using a treadmill, strength training of the arms and legs, and educational discussions to support symptom management based upon the information on the Your COVID Recovery platform.

Researchers found a statistically significant improvement in exercise capacity, as measured by scores of distance travelled and ability to keep going without a rest using incremental and endurance shuttle-walking tests. They also found that fatigue improved by 5 points on the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale over the six-week period. In addition, participants demonstrated improvement in their overall wellbeing and cognition, as measured by standardised clinical assessment tools.

Participants were referred through a hospital discharge follow-up telephone assessment, at a face-to-face COVID-19 clinic assessment, or via their GP. Individuals were offered the opportunity to take part if they displayed physical and/or psychological symptoms that were affecting their daily activities. Patients were excluded if they demonstrated acute symptoms, or were not medically stable (such as uncontrolled diabetes) or had only symptoms that were deemed unlikely to benefit from a pulmonary rehabilitation programme, such as loss of taste or smell.

Of the participants, there was an even split between men and women, with an average of 58 years. Eighty-seven per cent of participants were admitted to hospital with COVID-19, staying on average 10 days in hospital. Fourteen per cent required mechanical ventilation and were treated in an Intensive Care Unit. Four individuals had a pre-existing respiratory condition, such as asthma or chronic obstructive pulmonary disease (COPD).

Dr Enya Daynes, specialist pulmonary rehabilitation and research physiotherapist at Leicester’s Hospitals and lead author of the study, said: “We know that COVID-19 survivors present with a wide variety of symptoms and that a one-size-fits-all approach to managing these would not be appropriate. However, there are some overlap between the needs of COVID-19 survivors and patients who have accessed pulmonary rehabilitation [PR] for other conditions, such as COPD. So we modified our well-established PR course for COVID-19 survivors and measured their symptoms to assess whether the programme could be of potential benefit.

“We found there were significant improvements in clinical outcomes of walking capacity and symptoms of fatigue, cognition and respiratory symptoms – factors that patients tell us most affect their quality of life.”

Professor Sally Singh, head of cardiac and pulmonary rehabilitation at Leicester’s Hospitals, professor at the University of Leicester and senior author of the paper, said: “This adapted rehabilitation programme for individuals following COVID-19 has demonstrated promising improvements in clinical outcomes. There were no drop-outs due to worsening symptoms and the high completion rate suggests that patients found it to be an acceptable treatment.

“There has been concern that rehabilitation may worsen or trigger symptoms of post-viral fatigue and that exercise therapy may exacerbate fatigue. The exercise element of this programme is progressed by staff experienced in delivering pulmonary and cardiac rehabilitation programmes in line with patient’s symptoms throughout the programme. Our results did not show that fatigue worsened among the group of patients on the study, and that many of their symptoms improved. This suggests an adapted pulmonary rehabilitation courses can be part of a spectrum of patient-centred and holistic approaches to treating the many different presentations of lasting COVID symptoms.”

The research team acknowledges that as a cohort study there is no control group of people with similar symptoms who did not embark on the modified pulmonary rehabilitation course to offer a comparison and that further studies with a larger patient population are needed to confirm their preliminary findings.

Exercise for Restless Legs Syndrome

Restless legs syndrome is a miserable health issue that compel the legs to want to move at night. There is not a lot known if doing any sort exercises is beneficial for restless legs syndrome and helping those with the condition get some sleep. Also what is not known is if it is useful, just what sort and type of exercises should be used.

This clinical trial was recently registered in which the researchers are going to study exercise in restless legs syndrome.

Here is a summary of the study:

Restless leg syndrome (RLS) is a very common neurological condition characterized by an uncontrollable desire to move the legs. Due to the traumatic effect of RLS on morbidity, the patient is negatively affected in many different directions. The duration and quality of sleep of the patients decrease, and their cognitive functions change. The prevalence or risk of anxiety and depression increases in this population. At the same time, the quality of life of patients is significantly reduced. Among the different pharmacological agents used in RLS, dopamine agonists are the most widely used. However, the reporting of serious and common side effects related to this treatment has led to non-pharmacological approaches in the treatment of RLS and the effectiveness of many different approaches has been investigated. The exercise approach, which is determined to be effective in the treatment of the disease, is a subject that has been little studied. The type, duration and frequency of optimal exercise could not be standardized. In addition, the effect of exercise on RLS patients has been investigated in limited subjects. For this reason, the aim of our study is to examine the effect of different exercise programs on symptoms, sleep, cognitive functions, quality of life, psychological status and fatigue in patients with RLS.